A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease

Bone Marrow Transplantation

Volumn 35, Issue 6, 2005, Pages 557-566

  Hahn, Theresa ^a   Benekli, M ^a   Wong, C ^a   Moysich, K B ^a   Hyland, A ^a   Michalek, A M ^a   Alam, A ^a   Baer, M R ^a   Bambach, B ^a   Czuczman, M S ^a   Wetzler, M ^a   Becker, J L ^a   McCarthy, P L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Allogeneic BMT; Autologous BMT; Hodgkin's disease; Prognostic model

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; OKT 3; PLATINUM DERIVATIVE; TACROLIMUS; THIOTEPA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FATALITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SAMPLE SIZE; SIDE EFFECT; TREATMENT OUTCOME; VALIDATION PROCESS;

ADULT; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GRAFT SURVIVAL; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TIME; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 20144388374     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704789     Document Type: Article

References (58)

1. Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999; 93: 761-779.
2. Fung HC, Nademanee AP. Approach to Hodgkin's lymphoma in the new millenium. Hematol Oncol 2002; 20: 1-15.
3. Longo DL, Duffey PL, Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability of cure. J Clin Oncol 1992; 10: 210-218.
4. Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534.
5. Rapoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11: 2351-2361.
6. Bierman PJ, Bagin RG, Jagannath S et al. High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol 1993; 4 767-773.
7. Nademanee A, O'Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood 1995; 85 1381-1390.
8. Horning SJ, Chao NJ, Negrin RS et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
9. Sweetenham JW, Taghipour G, Milligan D et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Bone Marrow Transplant 1997; 20: 745-752.
10. Lazarus HM, Rowlings RA, Zhang M-J et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 1999; 17: 534-545.
11. Lazarus HM, Loberiza FR, Zhang M-J et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001; 27: 387-396.
12. Sureda A, Arranz R, Iriondo A et al. Autologous stem cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/ transplante autologo de medula osea Spanish cooperative group. J Clin Oncol 2001; 19: 1395-1404.
13. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
14. Andre M, Henry-Amar M, Pico J-L et al. Comparison of high-dose therapy and autologous stem cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case control study. J Clin Oncol 1999; 17: 222-229.
15. Anselmo AP, Meloni G, Cavalieri E et al. Conventional salvage chemotherapy vs high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Ann Hematol 2000; 79 79-82.
16. Yuen AR, Rosenberg SA, Hoppe RT et al. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-822.
17. Moskowitz CH, Kewalramani T, Nimer SD et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124: 645-652.
18. Phillips GL, Reece DE, Barnett MJ et al. Allogeneic marrow transplantation for refractory Hodgkin's disease. J Clin Oncol 1989; 7: 1039-1045.
19. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572-578.
20. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996; 14 1291-1296.
21. Jones RJ, Piantadosi S, Mann RB et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1990; 8: 527-537.
22. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
23. Anderson JE, Litzow MR, Appelbaum FR et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993; 11: 2342-2350.
24. Akpek G, Ambinder RF, Piantadosi S et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314-4321.
25. Nachbaur D, Oberaigner W, Fritsch E et al. Allogeneic or autologous stem cell transplantation (SCT) for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma: a single center experience. Eur J Haematol 2001; 66: 43-49.
26. Gobbi PG, Zinzani PL, Broglia C et al. Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer 2001; 91: 1467-1478.
27. Gobbi PG, Cavalli C, Federico M et al. Hodgkin's disease prognosis: a directly predictive equation. Lancet 1988; 1: 675-679.
28. Wagstaff J, Gregory WM, Swindell R et al. Prognostic factors for survival in Stage III B and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres. Br J Cancer 1988; 58: 487-492.
29. Straus DJ, Gaynor JJ, Myers J et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 7: 1173-1186.
30. Carella AM, Carlier P, Congiu A et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ ABVD protocol. Bone Marrow Transplant 1991; 8: 99-103.
31. Proctor SJ, Taylor P, Donnan P, et al, with the members of the Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. Eur J Cancer 1991; 27: 624-629.
32. Gobbi PG, Comelli M, Grignani GE et al. Estimate of expected survival at diagnosis in Hodgkin's disease: a means of weighting prognostic factors and a tool for treatment choice and clinical research. A report from the International Database on Hodgkin's Disease (IDHD). Haematologica 1994; 79: 241-255.
33. Lee SM, Radford JA, Ryder WDJ et al. Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. Br J Cancer 1997; 75: 110-115.
34. Ferme C, Bastion Y, Brice P et al. Prognosis of patients with advanced Hodgkin's disease. Evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer 1997; 80: 1124-1133.
35. Hasenclever D, Diehl V, for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score to predict tumor control in advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
36. Stiff PJ, Unger JM, Forman SJ et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003; 9: 529-539.
37. Moskowitz CH, Nimer SD, Zelenetz AD et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
38. Josting A, Franklin J, May M et al. New Prognostic Score based on treatment outcomes of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002; 20: 221-230.
39. Alidina A, Lawrence D, Ford LA et al. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biol Blood Marrow Transplant 1999; 5: 322-327.
40. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
41. Brown RA, Wolff SN, Fay JW et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first untreated relapse: a study by the North American Marrow Transplant Group. Blood 1995; 85: 1391-1395.
42. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
43. Alam AR, Younis T, Hahn T et al. High dose therapy and autologous hematopoietic stem cell transplantation (autoHSCT) with an intensive VCB conditioning regimen for relapsed and refractory Hodgkin's disease. Blood 2002; 100: 863a (abstr. 3404).
44. Santos GW, Tutschka PJ, Brookmeyer R. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
45. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
46. Nash RA, Pepe MS, Storb R et al. Acute graft-vs-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
47. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporine, methotrexate and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-vs-host disease. N Engl J Med 1993; 329: 1225-1229.
48. Shepherd JD, Shore TB, Reece DE et al. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 1988; 3: 553-557.
49. Alam AR, Baer MR, Bernstein S et al. Phase II clinical trial of OKT3 for acute graft-vs-host disease (GVHD) prophylaxis in allogeneic bone marrow transplantation (alloBMT). Blood 1997; 90 102a (abstr.).
50. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A matched sibling donors. Transplantation 1974; 18: 295-304.
51. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
52. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
53. Cox DR, Oakes D. Analysis of Survival Data. Chapman and Hall: New York, 1984.
54. Qazilbash MH, Devetten MP, Abraham J et al. High-dose therapy and autologous stem cell transplantation in relapsed and refractory Hodgkin's disease: outcome based on a prognostic model. Acta Haematol 2003; 110: 173-178.
55. Carella AM, Cavaliere M, Lerma E et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral blood hematopoietic stem cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 3918-3924.
56. Anderlini P, Giralt S, Andersson B et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26: 615-620.
57. Branson K, Chopra R, Kottaridis PD et al. Role of nonmyeloablative allogeneic stem cell transplantation after failure of autologous transplantation in patients with lympho-proliferative malignancies. J Clin Oncol 2002; 20: 4022-4031.
58. Cooney JP, Stiff PJ, Toor AA, Parthasarathy M. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective. Biol Blood Marrow Transplant 2003; 9: 177-182.